第一弹和标题收入从1650.9万美元更正为1651.7万美元
路透5月12日 - Immunitybio Inc IBRX.O:
Immunitybio第一季度营收为1651.7万美元,而IBES预计为1600万美元。IBS预计为1600万美元
免疫生物第一季度营业收入-6442.9万美元
免疫生物第一季度净收入-1.29666亿美元
资料来源 ID:nBw2V17NWa
更多公司报导:IBRX.O
(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.